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AbstrACt
Purpose To describe the rationale, methods and research 
potential of eye and vision measures available in UK 
Biobank.
Participants UK Biobank is a large, multisite, prospective 
cohort study. Extensive lifestyle and health questionnaires, 
a range of physical measures and collection of biological 
specimens are collected. The scope of UK Biobank was 
extended midway through data collection to include 
assessments of other measures of health, including eyes 
and vision. The eye assessment at baseline included 
questionnaires detailing past ophthalmic and family 
history, measurement of visual acuity, refractive error 
and keratometry, intraocular pressure (IOP), corneal 
biomechanics, spectral domain optical coherence 
tomography (OCT) of the macula and a disc–macula 
fundus photograph. Since recruitment, UK Biobank has 
collected accelerometer data and begun multimodal 
imaging data (including brain, heart and abdominal MRI) 
in 100 000 participants. Dense genotypic data and a panel 
of 20 biochemistry measures are available, and linkage to 
medical health records for the full cohort has begun.
Findings to date A total of 502 665 people aged between 
40 and 69 were recruited to participate in UK Biobank. 
Of these, 117 175 took part in baseline assessment of 
vision, IOP, refraction and keratometry. A subgroup of 
67 321 underwent OCT and retinal photography. The 
introduction of eye and vision measures in UK Biobank 
was accompanied by intensive training, support and a data 
monitoring quality control process.
Future plans UK Biobank is one of the largest prospective 
cohorts worldwide with extensive data on ophthalmic 
diseases and conditions. Data collection is an ongoing 
process and a repeat of the baseline assessment including 
the questionnaires, measurements and sample collection 
will be performed in subsets of 25 000 participants every 
2–3 years. The depth and breadth of this dataset, coupled 
with its open-access policy, will create a powerful resource 
for all researchers to investigate the eye diseases in later 
life.
IntroduCtIon 
Ageing populations worldwide face an 
increasing burden of chronic and neurode-
generative diseases,1 resulting in substantial 
health and economic burdens.2 3 Chronic 
age-related eye diseases, such as age-related 
macular degeneration (AMD), diabetic reti-
nopathy (DR) and glaucoma, are leading 
causes of visual impairment in Western popu-
lations. Increased intraocular pressure (IOP) 
is one of the most significant risk factors for 
the development4 and progression5 of glau-
coma. A recent study from the UK Biobank 
demonstrated that factors including diabetes, 
height, smoking and black ethnicity have 
different associations with Goldmann-cor-
related IOP (IOPg) and corneal-compen-
sated IOP (IOPcc).6 Hence, suggesting that 
these factors are related to corneal biome-
chanical properties. In another UK Biobank 
study, 67 321 participants underwent optical 
coherence tomography (OCT) imaging 
of both eyes.7 The OCT is a non-invasive 
imaging system that provides high-resolution, 
cross-sectional images of the retina, retinal 
nerve fibre layer (RNFL) and the optic nerve, 
aiding in the diagnosis and management of 
eye diseases.8 Loss of vision due to eye diseases 
has a considerable impact on an individual’s 
activities and quality of life.9 10 Identifying 
modifiable risk factors of common disabling 
diseases of later life may help develop preven-
tive strategies. These conditions are often 
caused by a combination of genetics, envi-
ronmental and lifestyle factors. Built on a 
strengths and limitations of this study
 ► UK Biobank is the largest prospective cohort with 
extensive measures on ophthalmic diseases and 
conditions.
 ► Repeated physical measures every few years and 
linkage to National Health Service records will pro-
vide valuable information on health outcomes.
 ► A large number of incident cases of eye diseases in 
5 years will allow the detection and quantification of 
small effect sizes.
 ► A low response rate (5.5%).
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foundation laid by the Human Genome Project,11 the 
last decade has seen dramatic advances in the under-
standing of molecular mechanisms in the human health 
and disease. A myriad of studies using traditional linkage 
methods and genome-wide association studies12–14 have 
now raised questions about the role of gene–gene (GxG) 
and gene–environment (GxE) interaction in deter-
mining disease susceptibility.15 16 Extensive information 
on environment and lifestyle in conjunction with biolog-
ical samples are crucial to assess GxE interactions.
To avoid the potential for reverse causality and minimise 
recall bias, exposures should be measured before they are 
affected by disease or its treatment. Prospective cohorts 
offer many advantages for assessing the combined effects 
of genes, environment and lifestyle factors and its associa-
tion with various health outcomes. The prospective nature 
of these cohorts allows the exposures to be recorded 
before the disease onset, and a wide range of diseases to 
be investigated, including those that may be challenging 
to study retrospectively.17 Furthermore, the overall bene-
ficial and adverse effects of a specific exposure on the life-
time risks of numerous diseases can be examined. Only a 
small proportion of individuals will develop the disease 
and the effects of various exposures on disease develop-
ment are likely to be modest. Hence, to address questions 
of GxG and GxE interaction, prospective studies need 
to include a large number of participants, with several 
hundred thousand participants.18 19 However, there is a 
lack of large prospective studies at such a scale that allow 
investigation of risk factors or gene–environmental inter-
action of eye diseases.
UK Biobank (https://www. ukbiobank. ac. uk/) is a 
large-scale multisite cohort study, conceived to provide a 
resource for the scientific community to examine genetic 
and environmental risk factors for complex diseases of 
middle and old age in the UK population. UK Biobank 
has collected extensive baseline questionnaire data, phys-
ical measures and biological samples, with comprehensive 
follow-up and characterisation of many different health 
outcomes.20 Towards the end of the baseline phase, the 
UK Biobank Steering Committee advised the broadening 
of the scope of the study to include more detailed exam-
ination of participants, including assessment of arterial 
stiffness, a hearing test, additional cognitive function 
tests, cardiorespiratory fitness, collection of whole blood 
and saliva, as well as an examination of eyes and vision. 
The UK Biobank eye and vision data provide researchers 
with a unique opportunity to access a very large dataset 
containing detailed ocular phenotypic information, 
together with rich biomarker variables, dense genotyping 
and extensive information on lifestyle variables, medical 
history and healthcare episodes, thus giving unique 
research resource. As such, UK Biobank offers compre-
hensive data to explore novel aetiological associations, 
risk factors and to make evidence-based recommenda-
tions on policy. This report aims to describe the methods 
and the baseline characteristics of the participants who 
underwent eye and vision assessment in UK Biobank.
Cohort desCrIPtIon
Whole uK biobank cohort
UK Biobank is a large, multisite, study of 502 656 UK 
residents aged between 40 and 69 years who were regis-
tered with the National Health Service (NHS). The 
overall study protocol (http://www. ukbiobank. ac. uk/ 
resources/) and protocols for individual tests (http:// 
biobank. ctsu. ox. ac. uk/ crystal/ catalogs. cgi) are available 
online. Briefly, extensive baseline questionnaires and 
physical measures were obtained from 22 assessment 
centres between January 2006 and October 2010.20 21 This 
included data on sociodemographics, family history and 
early life exposures, psychosocial, environmental, life-
style, environmental and health status, hearing threshold 
and cognitive function as well as self-reported medical 
conditions. In addition to the baseline questionnaire, 
web-based questionnaires were included to obtain data 
on dietary intake, occupational history, cognitive func-
tion, mental health and gastrointestinal symptoms. In 
addition, mailed triaxial accelerometers will supplement 
the physical activity data in 100 000 participants.20
Physical examination included blood pressure, heart 
rate, hand grip strength, anthropometrics, spirom-
etry, bone density, arterial stiffness, fitness test. Biolog-
ical samples, including stored blood, urine and saliva 
samples, were collected to allow many different types of 
assay (eg, genetic, proteomic, metabolomics, biochemical 
and haematologic), (https://www. ukbiobank. ac. uk/)22 23 
providing a uniquely rich resource for investigating aeti-
ological risk factors and thereby assisting in the preven-
tion and treatment of many different conditions. The UK 
Biobank Axiom array was used for genotyping and the 
methods have been described in detail.23 Furthermore, 
UK Biobank launched the world’s largest health imaging 
study in 2014 ( www. imaging. ukbiobank. ac. uk) that aims 
to perform MRI of brain, heart and abdomen, carotid 
ultrasound and dual-energy X-ray absorptiometry body 
scans on 100 000 participants.24 A detailed follow-up of 
participants over a 20-year period is envisaged through 
data linkage to national electronic medical records. 
Thus, linking to NHS will provide valuable information 
on health outcomes (eg, mortality, cancer registrations, 
hospital admissions, primary care data, etc).
The key ethics and governance principles relating to 
UK Biobank are laid out in the Ethics and Governance 
Framework,22 prepared by the project funders. Major 
funders include Medical Research Council (MRC) and 
Wellcome Trust, while other funding bodies include 
Department of Health (DoH), Scottish Government 
and the Welsh Government, North West Development 
Agency, British Heart Foundation and Diabetes UK. All 
participants provided informed consent.
uK biobank eye and vision subcohort
Study location
Ocular measurements commenced in late 2009 at six 
assessment centres as an additional enhancement to the 
initial baseline measures. The six centres are distributed 
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across the UK, including Croydon and Hounslow in 
Greater London, Liverpool and Sheffield in Northern 
England, Birmingham in the Midlands and Swansea in 
Wales.6
Examination procedures
Questionnaires
Self-reported eye diseases, including glaucoma, DR 
and AMD, were obtained from self-administered 
questionnaires.
Measurements
The methods and protocol for the ocular examination 
component were designed by ophthalmologists from 
Moorfields Eye Hospital (MEH), London, UK. The core 
funding for the examination was provided by the Well-
come Trust, the MRC and the DoH. Additional support 
for training, implementation and quality control came 
from the NIHR Biomedical Research Centre at MEH. 
All ocular examinations were undertaken by trained 
personnel to ensure that the ocular measurements were 
acquired in a stepwise manner using standard operating 
procedures or instructions, and they had to pass a struc-
tured examination before the project started. The entire 
process including the teaching material was reviewed and 
moderated by an ophthalmologist from MEH, London, 
UK. The ocular examinations were conducted without 
pharmacological mydriasis and took an average time 
of 11 min to complete.7 Baseline eye examination was 
conducted from June 2009 to July 2010, subsequently, 
from August 2012 to June 2013, a subset of approximately 
20 000 underwent follow-up examination, including all 
eye measures.
Visual acuity
Visual acuity (VA) was measured using a logarithm of the 
minimum angle of resolution (LogMAR) chart (Preci-
sion Vision, LaSalle, Illinois, USA) on a computer screen 
under standard illumination. It follows the British Stan-
dards Institute,25 and the right eye was measured first. The 
test was performed with participants wearing the distance 
refraction at 4 m, or at 1 m if a participant was unable to 
read. Participants were asked to read each letter from the 
top of the chart and down as far as possible. The test was 
terminated when ≥2 letters are incorrect and recorded as 
LogMAR VA.
Refraction
Non-cycloplegic autorefraction was performed using the 
Tomey RC-5000 Auto Refkeratometer (Tomey, Nagoya, 
Japan) and the right eye was measured first. For each eye, 
up to 10 measurements were taken and each measure-
ment had a score between 0 and 9 (smaller scores indicate 
more reliable measurements). To ensure measurements 
were reliable, each reading achieved a score of ≤4.26
Intraocular pressure
IOP was measured using the Ocular Response Analyzer 
(ORA) (Reichert, Philadelphia, Pennsylvania, USA).27 
One measurement was taken for each eye and the right 
eye was measured first. The ORA uses a rapid pulse air to 
indent the cornea and an electro-optical system records 
the corneal deformation. Two applanation measure-
ments are recorded: (1) while the cornea moves inwards, 
achieving a first applanation state or flattening (P1); (2) 
when the cornea recovers from its slight concave state as 
the pressure decreases, and the cornea passes through a 
second applanated state (P2). Hence, P1 and P2 are air 
pressures that correspond with the two applanation states 
of the cornea.28 The average of the 2 ORA pressure values 
was calibrated against Goldmann applanation tonom-
eter to derive IOPg (mm Hg) A separate IOPcc reading 
(IOPcc=P1 and 0.43*P2) was derived to limit the differ-
ence before and after laser-assisted in situ keratomileusis 
(LASIK) surgery and has, therefore, limited influence 
from corneal biomechanics than those provided by Gold-
mann applanation tonometer.27 29
Corneal hysteresis
Corneal hysteresis (CH) is considered an indicator of 
corneal viscous energy damping and is derived as the 
difference between P1 and P2: CH=P1 and P2.
27 28
Optical coherence tomography
OCT images were obtained using a spectral domain OCT 
3-dimensional (3D OCT-1000 Mark II, Topcon, Japan). 
The scans were conducted in a darkened room under 
standard illumination without pupil dilation using a 3D 
macular volume scan (512 horizontal A-scans/B-scan; 
128 B-scans in a 6×6 mm raster pattern). The method-
ology of the OCT imaging has been described previ-
ously.7 30
Fundus photography
Colour photographs of the optic disc and macular 
were acquired using a Topcon 3D OCT-1000 Mark II 
system. The Topcon 3D OCT-1000 has a field angle 
of 45°, a digital zoom (2X, 4X), scanning range of 
6×6 mm, 4.5×4.5 mm, 3×3 mm and a scanning speed of 
18 000 A-scans per second. The horizontal and longi-
tudinal (depth) resolutions were ≤20 µm and 5–6 µm, 
respectively.31
data monitoring and quality assessment feedback
Daily monitoring of data collection was performed by UK 
Biobank using a custom-designed monitoring software 
(WACMAN). The WACMAN software monitored the 
data items collected and allowed individual operator’s 
performance to be reviewed—the number of measure-
ments skipped and the degree to which the data collected 
by the operator lay within the range of expected values. 
The performance of the technicians responsible for 
ophthalmic imaging was monitored to provide feedback 
to those producing substandard quality images within 
three working days. This was achieved by grading the first 
100 photographs of each technician and at least 5% of all 
OCT images.
by copyright.
 o
n
 Septem
ber 3, 2019 at Queen's University Belfast. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025077 on 21 February 2019. Downloaded from 
4 Chua SYL, et al. BMJ Open 2019;9:e025077. doi:10.1136/bmjopen-2018-025077
Open access 
Patient and public involvement
UK Biobank maintains a website to keep participants 
and researchers up to date on the study, which contains 
a news feed (http://www. ukbiobank. ac. uk/ news/) and 
feedback service. In addition, UK Biobank has a twitter 
feed.
There is an annual scientific meeting which is recorded 
and available to the public as webcast.
The study was set up by the MRC, DoH and Wellcome 
Trust with input from major patient representative organ-
isations (British Heart Foundation and Cancer Research 
UK) http://www. ukbiobank. ac. uk/ public- consultation/
statistical analysis
The baseline ocular characteristics were analysed and 
presented as mean±SD for continuous variables and 
number (%) for categorical variables. Statistical analyses 
were performed using STATA software V.13.0 (StataCorp).
results
Findings to date
In total, ocular measures including VA, refraction and 
IOP data were measured in approximately 117 175 people 
aged 40–69 years. Of these, OCT imaging and fundus 
photography were performed in 67 321 (57.5%) partici-
pants. Figure 1 describes the number of participants with 
eye measures at baseline and first repeat visit. Table 1 
describes the baseline characteristics of participants in 
the total cohort, and among participants with various 
ocular measurements at baseline and at first repeat visits. 
Compared with the whole UK Biobank cohort, partic-
ipants with baseline VA and OCT measures consisted 
of a higher proportion of Asians, blacks and mixed/
others ethnic groups and had more positive Townsend 
Deprivation Index. Compared with participants with base-
line eye measures, those with repeat visit of VA or OCT 
data were older, more likely male, of white ethnic back-
ground, had the educational level of degree and above, 
had more negative Townsend Deprivation Index or better 
socioeconomic status and less likely to smoke.
Table 2 summarises the number of participants 
completing each test and the summary measures for 
these tests. The VA and refractive error measures were 
quite similar at baseline and at the first repeat visits. Mean 
VA was approximately 0.0 LogMAR at both visits. At both 
visit, the mean spherical equivalent refraction was −0.3 
D. Approximately 60% of participants were non-myopic, 
while the proportion of participants with low, moderate 
and high myopia were 24%, 11% and 5%, respectively. 
Participants’ mean IOP was slightly higher at first repeat 
visit than at baseline. The mean IOPg ranged from 
15.7 mm Hg to 16.2 mm Hg, while IOPcc ranged from 
16.0 mm Hg to 16.5 mm Hg. The proportion of partici-
pants with ocular hypertension was 12% at baseline and 
16% at first repeat visit. Projected number of new cases of 
eye diseases including AMD, cataract and primary open 
angle glaucoma (POAG) expected to occur among the 
whole UK Biobank cohort and subcohort during the 
Figure 1 Flow chart of participants with the eye measures at baseline and first repeat visit in the UK Biobank. IOP, intraocular 
pressure; OCT, optical coherence tomography; VA, visual acuity. 
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period of 25 years follow-up (table 3).32 By 2023, the 
expected number of new cases of any AMD, cataract 
and POAG were around 11 753, 107 702 and 8704 in the 
whole cohort, respectively, with around 14% of these cases 
occurring in the ocular subcohort. From 2023 to 2033, 
the expected number of new cases of any AMD increased 
by 3.5 times, while the expected number of cataract and 
POAG increased by two times.
Findings from the UK Biobank eye data showed that 
first-born individuals were more often myopic than 
non-first-born,33 which confirms previous findings.34 35 
New findings include the discovery of 112 loci, including 
68 novel loci, associated with IOP and the development 
of POAG. Several loci suggest the importance of angio-
poietin-receptor tyrosine kinase (ANG-TEK) in signalling 
IOP regulation, thus suggesting ANG-TEK to be a thera-
peutic target. In individuals without neurodegeneration, 
thinner RNFL was associated with worse cognitive func-
tion and more likely to have future cognitive decline.36 
The use of deep-learning models predicted cardiovas-
cular risk factors such as age (mean absolute error within 
3.26 years), gender (area under the curve (AUC)=0.97), 
smoking status (AUC=0.71), systolic blood pressure 
(mean absolute error within 11.23 mm Hg) and major 
adverse cardiac events (AUC=0.70).37
dIsCussIon
Common age-related eye diseases, including AMD, 
DR, glaucoma and myopia, are leading causes of visual 
impairment,38 and have both genetic and environmental 
contributions. Smoking and age are the most consistently 
observed non-genetic risk factors for AMD,39 and several 
established genetic risk factors have been identified.40 41 
Significant gene–environmental interactions have been 
identified for complement factor H gene and smoking 
for AMD.42 However, limitations exist and generalisability 
Table 2 Ocular characteristics of participants in the UK Biobank at baseline visit and at the first repeat visit
Type of eye test
Summary measure Baseline visit First repeat visit
Description N Mean±SD/(%) N Mean±SD/(%)
Visual acuity Mean±SD LogMAR in RE 116 068 0.03±0.21 20 162 0.00±0.21
Mean±SD LogMAR in LE 116 071 0.02±0.21 20 153 0.00±0.22
Refraction Mean±SD spherical equivalent in RE (D) 114 269 −0.36±2.74 19 505 −0.34±2.86
Mean±SD spherical equivalent in LE (D) 113 895 −0.30±2.76 19 381 −0.31±2.90
No of non-myopes (≤−0.50 D) 69 871 60.8 11 636 59
No (%) of low myopes (≤−2.99 D)* 27 048 23.5 4656 23.6
No (%) of moderate myopes (≤−3.00 to ≥−5.99 D)* 12 033 10.5 2336 11.8
No (%) of high myopes (≤−6.00 D)* 5917 5.2 1095 5.6
Ocular Response 
Analyzer
Mean±SD IOPg in RE (mm Hg) 112 292 15.88±3.97 19 515 16.19±4.28
Mean±SD IOPg in LE (mm Hg) 111 961 15.74±4.02 19 460 16.05±4.30
Mean±SD IOPcc in RE (mm Hg) 112 292 16.08±4.35 19 515 16.52±5.05
Mean±SD IOPcc in LE (mm Hg) 111 962 16.01±4.40 19 460 16.00±4.84
No (%) of ocular hypertension (IOPg >21 mm Hg)† 14 192 12.5 3182 16.2
*Myopia severity defined from either eye.
†Ocular hypertension defined from either eye.
IOPcc, corneal-compensated intraocular pressure; IOPg, Goldmann-correlated intraocular pressure; LE, left eye; LogMAR, logarithm of the 
minimum angle of resolution; RE, right eye. 
Table 3 Predicted number of new cases of eye diseases 
expected to occur during the first 25 years of follow-up in 
UK Biobank
Type of eye 
disease 2018 2023 2028 2033
Whole cohort
AMD
  Any AMD 5455 11 753 22 727 41 205
  NV AMD 3989 8584 16 577 30 007
  GA AMD 3107 6718 13 030 23 663
  Cataract 61 483 107 702 157 499 204 220
  POAG 5103 8704 13 113 18 296
Ocular subcohort*
AMD
  Any AMD 766 1649 3186 5761
  NV AMD 560 1204 2322 4198
  GA AMD 437 944 1829 3317
  Cataract 8593 14 984 21 787 28 093
  POAG 708 1207 1817 2532
Adapted from Desai et al.32
*Ocular subcohort who had ophthalmic assessment at baseline, 
including retinal imaging.
AMD, age-related macular degeneration; GA, geographic atrophy; 
NV, neovascular; POAG, primary open angle glaucoma.
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of the findings is uncertain. Hence, future prospective 
studies of larger sample size would help to clarify the 
issue. The UK is in an ideal position to undertake ambi-
tious ‘big data’ health sciences research, given the exten-
sive coverage of the NHS and various detailed health 
record systems. UK Biobank has begun to harness these 
strengths to deliver epidemiological research at scale. 
Repeating detailed physical measures every few years in 
subsets of 20–25 000 participants adds a powerful longi-
tudinal dimension, with health-related outcomes being 
tracked through linkage to NHS records including death 
and cancer registers, hospital inpatient and outpatient 
episodes and primary care. Other health record linkage 
including data from national mental healthcare, resi-
dential history, laboratory and disease audit datasets, 
National Ophthalmology Database Audit, OpenEyes, 
Medisoft Ophthalmology, and may also include imaging, 
cancer screening and dental.20 To enhance accurate iden-
tification of health outcomes, additional methods such as 
cross-referencing against NHS case records, imaging and 
eye data or banked tissues will be used for validation and 
subclassification.
sCoPe oF eye dAtA
UK Biobank is among the largest eye and vision datasets 
globally. By 2023, >11 000 incident cases of AMD, >8000 
cases of POAG and about 107 000 cataract surgeries will 
have occurred in the whole UK Biobank cohort.32 This 
large number of new cases of eye diseases will provide 
substantial power for nested case–control studies to 
detect the main effect OR of 1.3 or higher.43 With the rise 
in ageing population, the rates of chronic eye diseases will 
increase. However, the rates of undiagnosed eye diseases 
remain high. Population-based studies reported that at 
least 50% of whites,44–47 and 55%–90% of Asians48–50 have 
undiagnosed glaucoma. Approximately 70% of undiag-
nosed cataracts were reported in USA51 and Singapore.52 
In addition to undiagnosed eye conditions, people were 
found to be unaware of their eye conditions. Previous 
population-based reported that only 5%–46% of those 
identified as having an eye disease (eg, AMD,53 cata-
ract,53 glaucoma and DR,54 accurately self-reporting their 
disease).55 Hence, linking to electronic health records 
is essential to ensure accuracy in identification of eye 
diseases. In UK Biobank, the overall self-reported glau-
coma rate was 1.7% among people aged 40–69 years.56 
This rate appears to be lower compared with White popu-
lations aged 40 years and older in the USA (2.08%),46 
Australia (2.0%)57 and Italy (2.9%).58
retInA And the CArdIovAsCulAr system
Retinal imaging has provided probably the richest data 
relating to eyes and vision in UK Biobank. In addition 
to giving unprecedented power to examine diseases of 
the eye, retinal morphometry can give insights into the 
diseases of the vascular and neurological systems. The 
retina shares similar embryological origin, anatomical 
features and physiological properties with the brain,59 it 
offers an accessible site to investigate the central nervous 
system in vivo.60 Using fundus photographs, retinal 
microvascular morphometry offers the prospect of mean-
ingful improvements in risk stratification in cardiovas-
cular disease.61 Table 4 summarises major longitudinal 
cohort studies (n<10 000) on an eye and systemic diseases 
that were performed among the Western populations62–68 
and Asian populations.69–75 Early signs of elevated risk 
of major systemic diseases, such as diabetes mellitus,76 
stroke,77–79 hypertension80 and cardiovascular diseases,81 
can be detected in the retinal blood vessels. The advent 
of powerful computer-based algorithms offers the pros-
pect of truly ground-breaking advances in medical care.37 
A recent study demonstrated that the application of 
deep learning to retinal fundus images can be used to 
predict cardiovascular risk factors such as age, gender 
and smoking status.37
Neurodegenerative diseases including Parkinson’s 
disease (PD), Alzheimer’s disease (AD) and multiple 
sclerosis (MS) all have a measurable effect on the retina. 
Recent studies using OCT showed differences in inner 
retinal layers between the normal population and partic-
ipants with PD,82 AD83 and MS.84 Studies have shown 
reduction in the ganglion cell layer along with the inner 
plexiform layer in patients with AD compared with 
healthy controls,85–87 while others reported thinning in 
the RNFL, especially in the superior and inferior quad-
rants.83 88–90 With a large cohort and detailed measure-
ments at multiple time points, the UK Biobank is able to 
assess if changes in the eye precede development of these 
conditions or are a consequence from the neurodegener-
ative conditions.
Comparison with other cohorts, biobanks and consortia
Table 5 describes large prospective cohorts (>10 000) 
that examine associations with eye diseases. European 
studies include the Rotterdam Study of 14 926 partici-
pants aged 45 years or older91 and the Gutenberg Health 
Study of 14 700 participants aged 35–74 years.92 In Asia, 
the Kangbuk Samsung Health Study performed health 
screening on 281 238 employees aged 20 years and older. 
However, there are limited ocular measurements with 
the KSH study.93 94 Large prospective studies are well 
suited for investigating the risk factors for diseases and 
could either be conducted as a biobank such as the UK 
Biobank,22 China Kadoorie Biobank95 and The American 
Cancer Society’s Cancer Prevention Study 396 or a consor-
tium such as the P3G consortium,
97 National Cancer Insti-
tute Cohort Consortium,98 Cohorts for Heart and Aging 
Research in Genomic Epidemiology99 and European Eye 
Epidemiology (E3) consortium. However, eye measures 
are not available on most of these large prospective studies 
except the UK Biobank and E3 consortium. The major 
differences between the biobank design and consortia are 
that the latter are often developed by pooling data from 
different studies with disparate consent/governance 
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procedures that may limit the power to address previously 
unanticipated research questions.100 Moreover, there 
is more variability in sampling, measurements of expo-
sures and identification of diseases ascertained.101 102 In 
contrast, biobanks are usually planned in advance with 
uniformity in collection of samples and genotyping has 
been carried out according to a predetermined strategy. 
Thus, consortia are typically regarded as less robust 
because of problems with direct and imputed genotyping, 
and non-standardised diagnostic criteria.
strengths and limitations
UK Biobank is the only prospective study with a very 
large sample size (>100 000) of participants with a range 
of eye measures. With the projected number of new 
cases diagnosed with a range of eye diseases, it will allow 
researchers to investigate the genetic, environmental and 
lifestyle risk factors of various eye diseases. In addition, 
there are intensive methods to ascertain outcomes with 
electronic and semiautomated sources for validation and 
sub classification.20
Despite the scope of eye data collected in the UK 
Biobank, limitations exist within the study. One important 
limitation of UK Biobank was its low response rate 
(5.5%), and that participants were more likely to be from 
a healthier, more affluent sector of the UK population. 
However, it is unlikely that the direction of the associa-
tion is opposite in respondents and non-respondents, and 
hence representativeness is not a major concern. The UK 
Biobank was not set up to be representative of the general 
UK population. More importantly, the large sample size 
and extensive exposures allow for valid scientific infer-
ences of associations between exposures and health 
outcomes that are generalisable to the wider population. 
In addition, a large number of cases allow the detection 
and quantification of small effect sizes. Eye measure-
ments were performed in 6 out of 22 of the assessment 
centres and participants with eye measures tend to have 
an education level of degree and above compared with 
the whole UK Biobank cohort. Hence, they may come 
from a more affluent sector and may not represent the 
whole UK Biobank cohort. The first repeat eye measure 
was only performed in approximately 20 000 participants. 
However, a repeat of the baseline visit will be conducted 
every few years in subsets of 20–25 000 participants. The 
self-reported nature of eye diseases may result in recall 
bias and misclassification error. However, the biases 
should be minimal as the ascertainment of outcomes will 
be conducted through linkages to national healthcare 
database, relevant administrative databases and analysis 
of available phenotypic data. We have access to medical 
records.32
CollAborAtIon
UK Biobank aims to provide open access data for 
health-related research and the data are made available 
to all bona fide researchers from the academic, charity, 
public and commercial sectors, both in the UK and inter-
nationally, without preferential or exclusive access for 
any user.20 All interested researchers may apply to access 
the data via an online application. Strict guidelines are 
in place to help ensure anonymity and confidentiality of 
participants’ data and samples.103
ConClusIon
UK Biobank Eye and Vision data would allow investigation 
of the factors leading to the onset and disease progression 
of major eye diseases. In addition, the ocular phenotypes 
could be explored with systemic diseases such as diabetes, 
hypertension and neurological diseases. In conclusion, 
the extensive exposures and health outcomes available 
in the UK Biobank will provide scientists with insights 
into the predictors of ocular and systemic diseases, 
allowing customised treatment therapies and interven-
tions tailored to the individual patient. Furthermore, its 
collaborative and multidisciplinary research allows scien-
tists to use known or innovative methods to explore and 
further develop techniques and treatment strategies that 
could have a major impact on the field of biomedical, 
behavioural or clinical research.
Acknowledgements We would like to acknowledge Tim Sprosen, Alan Young, Sir 
Rory Collins (all Oxford University Clinical Trials Service Unit and Epidemiological 
Studies Unit) and all those who had contributed to design and development of the 
UK Biobank eye data resource.
Collaborators UK Biobank Eye & Vision Consortium: The UK Biobank Eye & Vision 
Consortium members are Tariq Aslam, PhD, Manchester University, Sarah A. 
Barman, PhD, Kingston University, Jenny H. Barrett, PhD, University of Leeds, Paul 
Bishop, PhD, Manchester University, Peter Blows, BSc, NIHR Biomedical Research 
Centre, Catey Bunce, DSc, King’s College London, Roxana O. Carare, PhD, University 
of Southampton, Usha Chakravarthy, FRCOphth, Queens University Belfast, Michelle 
Chan, FRCOphth, NIHR Biomedical Research Centre, Sharon Y.L. Chua, PhD, NIHR 
Biomedical Research Centre, David P. Crabb, PhD, UCL, Philippa M. Cumberland, 
MSc, UCL Great Ormond Street Institute of Child Health, Alexander Day,PhD, 
NIHR Biomedical Research Centre, Parul Desai, PhD, NIHRBiomedical Research 
Centre, Bal Dhillon, FRCOphth, University ofEdinburgh, Andrew D. Dick, FRCOphth, 
University of Bristol, Cathy Egan, FRCOphth, NIHR Biomedical Research Centre, 
Sarah Ennis, PhD,University of Southampton, Paul Foster, PhD, NIHR Biomedical 
ResearchCentre, Marcus Fruttiger, PhD, NIHR Biomedical Research Centre, John 
E.J. Gallacher, PhD, University of Oxford, David F. GARWAY-HEATH MD FRCOphth - 
NIHR Biomedical Research Centre, Jane Gibson, PhD, University of Southampton, 
Dan Gore, FRCOphth, NIHR Biomedical Research Centre, Jeremy A. Guggenheim, 
PhD, Cardiff University, Chris J. Hammond, FRCOphth, King's College London, Alison 
Hardcastle, PhD,NIHR Biomedical Research Centre, Simon P. Harding, MD, University 
of Liverpool, Ruth E. Hogg, PhD, Queens University Belfast, Pirro Hysi, PhD, King's 
College London, Pearse A. Keane, MD, NIHR, Biomedical Research Centre, Sir 
Peng T. Khaw, PhD, NIHR Biomedical Research Centre, Anthony P. Khawaja, DPhil, 
NIHR Biomedical Research Centre, Gerassimos Lascaratos, PhD, NIHR Biomedical 
Research Centre, AndrewJ. Lotery, MD, University of Southampton, TomMacGillivray, 
PhD,University of Edinburgh, Sarah Mackie, PhD, University of Leeds, Keith Martin, 
FRCOphth, University of Cambridge, Michelle McGaughey,Queen’s University 
Belfast, Bernadette McGuinness, PhD, Queen’sUniversity Belfast, Gareth J. McKay, 
PhD, Queen's University Belfast, Martin McKibbin, FRCOphth, Leeds Teaching 
Hospitals NHS Trust, Danny Mitry, PhD, NIHR Biomedical Research Centre, Tony 
Moore, FRCOphth, NIHR Biomedical Research Centre, James E. Morgan, DPhil, 
Cardiff University, Zaynah A. Muthy, BSc, NIHR Biomedical Research Centre, Eoin 
O’Sullivan, MD, King's College Hospital NHS Foundation Trust,Chris G. Owen, PhD, 
University of London, Praveen Patel, FRCOphth, NIHR Biomedical Research Centre, 
Euan Paterson, BSc, Queens University Belfast, Tunde Peto, PhD, Queen's University 
Belfast, Axel Petzold, PhD, UCL, Jugnoo S. Rahi, PhD, UCL Great Ormond Street 
Institute of Child Health, Alicja R. Rudnikca, PhD, University ofLondon, Jay Self, 
PhD, University of Southampton, Sobha Sivaprasad, FRCOphth, NIHR Biomedical 
by copyright.
 o
n
 Septem
ber 3, 2019 at Queen's University Belfast. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025077 on 21 February 2019. Downloaded from 
11Chua SYL, et al. BMJ Open 2019;9:e025077. doi:10.1136/bmjopen-2018-025077
Open access
Research Centre, David Steel, FRCOphth, Newcastle University, Irene Stratton, MSc, 
Gloucestershire Hospitals NHS Foundation Trust, Nicholas Strouthidis, PhD, NIHR 
Biomedical Research Centre, Cathie Sudlow, DPhil, University of Edinburgh, Dhanes 
Thomas, FRCOphth, NIHR Biomedical Research Centre, Emanuele Trucco, PhD, 
University of Dundee, Adnan Tufail, FRCOphth, NIHR Biomedical Research Centre, 
Veronique Vitart, PhD, University of Edinburgh, Stephen A. Vernon, DM, Nottingham 
University Hospitals NHSTrust, Ananth C. Viswanathan, FRCOphth, NIHR Biomedical 
Research Centre, Cathy Williams, PhD, University of Bristol, Katie Williams, PhD, 
King's College London, Jayne V. Woodside, MRCOphth, PhD, Queen's University 
Belfast, Max M. Yates, PhD, University of East Anglia, Jennifer Yip, PhD, University of 
Cambridge, and Yalin Zheng, PhD, University of Liverpool. 
Contributors SYLC had full access to all the data in the study and took 
responsibility for the integrity of the data and accuracy of the data analysis. 
Concept and design: NA, AL, CS, PTK and PJF. Acquisition, analysis or interpretation 
of data: SYLC, DT, NA, AL, PD, PP, ZM, CS, TP, PTK and PJF. Critical revision of the 
manuscript for important intellectual content: all authors. Obtained funding: CS, PP, 
PTK, PJF and UK Biobank Eye and Vision Consortium. All authors read and critically 
revised the manuscript. All authors approved the final manuscript.
Funding The UK Biobank Eye and Vision Consortium is supported by grants from 
Moorfields Eye Charity, The NIHR Biomedical Research Centre at Moorfields Eye 
Hospital NHS Foundation Trust (BRC2_009) and UCL Institute of Ophthalmology and 
the Alcon Research Institute. 
disclaimer No funders had a direct role in the collection, management, analysis or 
interpretation of the data; preparation, review or approval of the manuscript; nor in 
the decision to submit the manuscript for publication. 
Competing interests This analysis was supported by the Eranda Foundation via 
the International Glaucoma Association in the design and conduct of the study. 
The UCL ORS and GRS programmes provided scholarship support for ZM, PTK, 
PJF, and PP and SYLC received salary support from the NIHR BRC at Moorfields 
Eye Hospital. PJF received support from the Richard Desmond Charitable Trust, via 
Fight for Sight, London. PJF reports personal fees from Allergan, Carl Zeiss, Google/
DeepMind and Santen, a grant from Alcon, outside the submitted work.
Patient consent Obtained.
ethics approval The North West Multi-center Research Ethics Committee 
approved the study (reference no., 06/MRE08/65), in accordance with the tenets of 
the Declaration of Helsinki. Detailed information about the study is available at the 
UK Biobank web site (https://www. ukbiobank. ac. uk/).
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement This research used data from the UK Biobank Resource, 
under data access request number 2112.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol 
2012;22:R741–R752.
 2. Organization WH. World report on ageing and health world health 
organization. 2015 http://www. who. int/ ageing/ publications/ world- 
report- 2015/ en/.
 3. Bommer C, Heesemann E, Sagalova V, et al. The global economic 
burden of diabetes in adults aged 20-79 years: a cost-of-illness 
study. Lancet Diabetes Endocrinol 2017;5:423–30.
 4. de Voogd S, Ikram MK, Wolfs RC, et al. Incidence of open-angle 
glaucoma in a general elderly population: the Rotterdam Study. 
Ophthalmology 2005;112:1487–93.
 5. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term 
progression in the early manifest glaucoma trial. Ophthalmology 
2007;114:1965–72.
 6. Chan MP, Grossi CM, Khawaja AP, et al. Associations with 
intraocular pressure in a large cohort: Results from the UK Biobank. 
Ophthalmology 2016;123:771–82.
 7. Keane PA, Grossi CM, Foster PJ, et al. Optical coherence 
tomography in the uk biobank study - rapid automated analysis 
of retinal thickness for large population-based studies. PLoS One 
2016;11:e0164095.
 8. Adhi M, Duker JS. Optical coherence tomography-current and 
future applications. Curr Opin Ophthalmol 2013;24:213–21.
 9. Williams GP, Pathak-Ray V, Austin MW. The social impact of visual 
impairment. Br J Ophthalmol 2007;91:986.
 10. Köberlein J, Beifus K, Schaffert C, et al. The economic burden of 
visual impairment and blindness: a systematic review. BMJ Open 
2013;3:e003471.
 11. Lander ES, Linton LM, Birren B, et al. Initial sequencing and 
analysis of the human genome. Nature 2001;409:860–921.
 12. Gemenetzi M, Yang Y, Lotery AJ. Current concepts on primary 
open-angle glaucoma genetics: a contribution to disease 
pathophysiology and future treatment. Eye 2012;26:355–69.
 13. Black JRM, Clark SJ. Age-related macular degeneration: genome-
wide association studies to translation. Genetics in Medicine 
2016;18:283–9.
 14. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide 
association study of age-related macular degeneration 
highlights contributions of rare and common variants. Nat Genet 
2016;48:134–43.
 15. Ottman R. Gene-environment interaction: definitions and study 
designs. Prev Med 1996;25:764–70.
 16. Tan Y-D, Fornage M, George V, et al. Parent–child pair design for 
detecting gene–environment interactions in complex diseases. Hum 
Genet 2007;121:745–57.
 17. Song JW, Chung KC. Observational studies: cohort and case-
control studies. Plast Reconstr Surg 2010;126:2234–42.
 18. Collins FS. The case for a US prospective cohort study of genes 
and environment. Nature 2004;429:475–7.
 19. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment 
and the value of prospective cohort studies. Nat Rev Genet 
2006;7:812–20.
 20. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access 
resource for identifying the causes of a wide range of complex 
diseases of middle and old age. PLoS Med 2015;12:e1001779.
 21. Allen N, Sudlow C, Downey P, et al. UK Biobank: Current status 
and what it means for epidemiology. Health Policy Technol 
2012;1:123–6.
 22. . UK Biobank. 2018. updated 2018. Available from: http://www. 
ukbiobank. ac. uk/
 23. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data 
on ~500,000 UK Biobank participants. bioRxiv, 2017.
 24. Miller KL, Alfaro-Almagro F, Bangerter NK, et al. Multimodal 
population brain imaging in the UK Biobank prospective 
epidemiological study. Nat Neurosci 2016;19:1523–36.
 25. Standard B. Test charts for determining distance visual acuity: BS 
4274-1968: London British Standards Institute, 1968.
 26. Cumberland PM, Bao Y, Hysi PG, et al. Frequency and distribution 
of refractive error in adult life: Methodology and findings of the UK 
biobank study. PLoS One 2015;10:e0139780.
 27. Luce DA. Determining in vivo biomechanical properties of the 
cornea with an ocular response analyzer. Journal of Cataract & 
Refractive Surgery 2005;31:156–62.
 28. Garcia-Porta N, Fernandes P, Queiros A, et al. Corneal 
biomechanical properties in different ocular conditions and new 
measurement techniques. ISRN Ophthalmol 2014;2014:1–19.
 29. Medeiros FA, Weinreb RN. Evaluation of the influence of corneal 
biomechanical properties on intraocular pressure measurements 
using the ocular response analyzer. J Glaucoma 2006;15:364–70.
 30. Patel PJ, Foster PJ, Grossi CM, et al. Spectral-domain optical 
coherence tomography imaging in 67 321 adults: Associations 
with macular thickness in the UK Biobank study. Ophthalmology 
2016;123:829–40.
 31. . Topcon. Optical Coherence Tomography 3D OCT-1000
 32. Desai P, Minassian DC, Reidy A, et al. Number of incident cases 
of the main eye diseases of ageing in the UK Biobank cohort, 
projected over a 25-year period from time of recruitment. Br J 
Ophthalmol 2018:1–5.
 33. Guggenheim JA, Williams C. UK Biobank Eye and Vision Consortium. 
Role of Educational Exposure in the Association Between Myopia 
and Birth Order. JAMA Ophthalmol 2015;133:1408–14.
 34. Rudnicka AR, Owen CG, Richards M, et al. Effect of breastfeeding 
and sociodemographic factors on visual outcome in childhood and 
adolescence. Am J Clin Nutr 2008;87:1392–9.
 35. Guggenheim JA, McMahon G, Northstone K, et al. Birth order and 
myopia. Ophthalmic Epidemiol 2013;20:375–84.
 36. Ko F, Muthy ZA, Gallacher J, et al. Association of Retinal Nerve 
Fiber Layer Thinning With Current and Future Cognitive Decline: 
A Study Using Optical Coherence Tomography. JAMA Neurol 
2018;75:1198-1205.
by copyright.
 o
n
 Septem
ber 3, 2019 at Queen's University Belfast. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025077 on 21 February 2019. Downloaded from 
12 Chua SYL, et al. BMJ Open 2019;9:e025077. doi:10.1136/bmjopen-2018-025077
Open access 
 37. Poplin R, Varadarajan AV, Blumer K, et al. Prediction of 
cardiovascular risk factors from retinal fundus photographs via 
deep learning. Nat Biomed Eng 2018;2:158–64.
 38. World Health Organization. Prevention of blindness and visual 
impairment. http://www. who. int/ blindness/ causes/ en/
 39. Clemons TE, Milton RC, Klein R, et al. 3rd. Risk factors for the 
incidence of Advanced Age-Related Macular Degeneration in the 
Age-Related Eye Disease Study (AREDS) AREDS report no. 19. 
Ophthalmology 2005;112:533–9.
 40. Heiba IM, Elston RC, Klein BEK, et al. Sibling correlations and 
segregation analysis of age-related maculopathy: The beaver dam 
eye study. Genet Epidemiol 1994;11:51–67.
 41. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related 
maculopathy. Population-based familial aggregation study. Archives 
of ophthalmology 1998;116:1646–51.
 42. Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study 
of 2 major age-related macular degeneration susceptibility alleles 
and interactions with modifiable risk factors. Arch Ophthalmol 
2007;125:55–62.
 43. Hattersley AT, McCarthy MI. What makes a good genetic 
association study?. Lancet 2005;366:1315–23.
 44. Weih LM, Nanjan M, McCarty CA, et al. Prevalence and predictors 
of open-angle glaucoma: results from the visual impairment project. 
Ophthalmology 2001;108:1966–72.
 45. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-
angle glaucoma in Australia. The Blue Mountains Eye Study. 
Ophthalmology 1996;103:1661–9.
 46. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the 
prevalence of primary open-angle glaucoma. The Baltimore Eye 
Survey. JAMA 1991;266:369–74.
 47. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The 
Beaver Dam Eye Study. Ophthalmology 1992;99:1499–504.
 48. Chua J, Baskaran M, Ong PG, et al. Prevalence, risk factors, 
and visual features of undiagnosed glaucoma: The singapore 
epidemiology of eye diseases study. JAMA Ophthalmol 
2015;133:938–46.
 49. Vijaya L, George R, Baskaran M, et al. Prevalence of primary 
open-angle glaucoma in an urban south Indian population and 
comparison with a rural population. The Chennai Glaucoma Study. 
Ophthalmology 2008;115:648–54.
 50. Song W, Shan L, Cheng F, et al. Prevalence of glaucoma in a rural 
northern china adult population: a population-based survey in kailu 
county, inner mongolia. Ophthalmology 2011;118:1982–8.
 51. Varma R, Mohanty SA, Deneen J, et al. Burden and predictors of 
undetected eye disease in Mexican-Americans: the Los Angeles 
Latino Eye Study. Med Care 2008;46:497–506.
 52. Chua J, Lim B, Fenwick EK, et al. Prevalence, risk factors, and 
impact of undiagnosed visually significant cataract: The singapore 
epidemiology of eye diseases study. PLoS One 2017;12:e0170804.
 53. Linton KL, Klein BE, Klein R. The validity of self-reported 
and surrogate-reported cataract and age-related macular 
degeneration in the Beaver Dam Eye Study. Am J Epidemiol 
1991;134:1438–46.
 54. Klein R, Klein BE, Moss SE, et al. The validity of a survey question 
to study diabetic retinopathy. Am J Epidemiol 1986;124:104–10.
 55. Patty L, Wu C, Torres M, et al. Validity of self-reported eye disease 
and treatment in a population-based study: the Los Angeles Latino 
Eye Study. Ophthalmology 2012;119:1725–30.
 56. Shweikh Y, Ko F, Chan MP, et al. Measures of socioeconomic 
status and self-reported glaucoma in the U.K. Biobank cohort. Eye 
2015;29:1360–7.
 57. Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence 
of glaucoma in the melbourne visual impairment project. 
Ophthalmology 1998;105:733–9.
 58. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma 
and intraocular pressure distribution in a defined population. The 
Egna-Neumarkt Study. Ophthalmology 1998;105:209–15.
 59. Patton N, Aslam T, Macgillivray T, et al. Retinal vascular image 
analysis as a potential screening tool for cerebrovascular disease: 
a rationale based on homology between cerebral and retinal 
microvasculatures. J Anat 2005;206:319–48.
 60. London A, Benhar I, Schwartz M. The retina as a window to 
the brain-from eye research to CNS disorders. Nat Rev Neurol 
2013;9:44–53.
 61. Welikala RA, Foster PJ, Whincup PH, et al. Automated arteriole and 
venule classification using deep learning for retinal images from the 
UK Biobank cohort. Comput Biol Med 2017;90:23–32.
 62. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence 
of macular edema in persons with type 1 diabetes. Ophthalmology 
2009;116:497–503.
 63. Joachim N, Mitchell P, Burlutsky G, et al. The incidence and 
progression of age-related macular degeneration over 15 years: The 
blue mountains eye study. Ophthalmology 2015;122:2482–9.
 64. Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of 
age-related cataract and cataract surgery in an older Australian 
population. The Blue Mountains Eye Study. Ophthalmology 
2008;115:808–14.
 65. Klein BE, Howard KP, Lee KE, et al. The relationship of cataract and 
cataract extraction to age-related macular degeneration: the Beaver 
Dam Eye Study. Ophthalmology 2012;119:1628–33.
 66. Chan MPY, Broadway DC, Khawaja AP, et al. Glaucoma and 
intraocular pressure in EPIC-Norfolk Eye Study: cross sectional 
study. BMJ 2017;358:j3889.
 67. Varma R, Chung J, Foong AW, et al. Four-year incidence and 
progression of visual impairment in Latinos: the Los Angeles Latino 
Eye Study. Am J Ophthalmol 2010;149:713–27.
 68. Choudhury F, Varma R, Klein R, et al. Age-related macular 
degeneration and quality of life in latinos: The los angeles latino eye 
study. JAMA Ophthalmol 2016;134:683–90.
 69. You QS, Xu L, Yang H, et al. Five-year incidence of visual 
impairment and blindness in adult Chinese the Beijing Eye Study. 
Ophthalmology 2011;118:1069–75.
 70. Wang YX, Xu L, Yang H, et al. Prevalence of glaucoma in North 
China: the Beijing Eye Study. Am J Ophthalmol 2010;150:917–24.
 71. Foong AW, Saw SM, Loo JL, et al. Rationale and methodology 
for a population-based study of eye diseases in Malay people: 
The Singapore Malay eye study (SiMES). Ophthalmic Epidemiol 
2007;14:25–35.
 72. Rosman M, Zheng Y, Wong W, et al. Singapore Malay Eye Study: 
rationale and methodology of 6-year follow-up study (SiMES-2). 
Clin Exp Ophthalmol 2012;40:557–68.
 73. Gao J, Liang Y, Wang F, et al. Retinal vessels change in primary 
angle-closure glaucoma: the Handan Eye Study. Sci Rep 
2015;5:9585.
 74. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic 
retinopathy in rural China: the Handan Eye Study. Ophthalmology 
2009;116:461–7.
 75. Ramakrishnan R, Nirmalan PK, Krishnadas R, et al. Glaucoma 
in a rural population of southern India. Ophthalmology 
2003;110:1484–90.
 76. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet 
2010;376:124–36.
 77. Baker ML, Hand PJ, Wang JJ, et al. Retinal signs and 
stroke: revisiting the link between the eye and brain. Stroke 
2008;39:1371–9.
 78. Cheung CY, Tay WT, Ikram MK, et al. Retinal microvascular 
changes and risk of stroke: the Singapore Malay Eye Study. Stroke 
2013;44:2402–8.
 79. Ikram MK, de Jong FJ, Bos MJ, et al. Retinal vessel diameters and 
risk of stroke: the Rotterdam Study. Neurology 2006;66:1339–43.
 80. Wong T, Mitchell P. The eye in hypertension. The Lancet 
2007;369:425–35.
 81. McGeechan K, Liew G, Macaskill P, et al. Meta-analysis: retinal 
vessel caliber and risk for coronary heart disease. Ann Intern Med 
2009;151:404–13.
 82. Lee JY, Ahn J, Kim TW, et al. Optical coherence tomography in 
Parkinson’s disease: is the retina a biomarker? J Parkinsons Dis 
2014;4:197–204.
 83. Coppola G, Di Renzo A, Ziccardi L, et al. Optical coherence 
tomography in alzheimer’s disease: A meta-analysis. PLoS One 
2015;10:e0134750.
 84. Garcia-Martin E, Ara JR, Martin J, et al. Retinal and optic nerve 
degeneration in patients with multiple sclerosis followed up for 5 
Years. Ophthalmology 2017;124:688–96.
 85. Cheung CY, Ong YT, Hilal S, et al. Retinal ganglion cell analysis 
using high -definition optical coherence tomography in patients with 
mild cognitive impairment and Alzheimer’s disease. J Alzheimers 
Dis 2015;45:45–56.
 86. Cunha LP, Lopes LC, Costa-Cunha LV, et al. Macular thickness 
measurements with frequency domain-oct for quantification of 
retinal neural loss and its correlation with cognitive impairment in 
Alzheimer’s disease. PLoS One 2016;11:e0153830.
 87. Ferrari L, Huang SC, Magnani G, et al. Optical coherence 
tomography reveals retinal neuroaxonal thinning in frontotemporal 
dementia as in alzheimer’s disease. J Alzheimers Dis 
2017;56:1101–7.
 88. Ascaso FJ, Cruz N, Modrego PJ, et al. Retinal alterations in mild 
cognitive impairment and Alzheimer’s disease: an optical coherence 
tomography study. J Neurol 2014;261:1522–30.
 89. Garcia-Martin E, Satue M, Fuertes I, et al. Ability and reproducibility 
of Fourier-domain optical coherence tomography to detect retinal 
by copyright.
 o
n
 Septem
ber 3, 2019 at Queen's University Belfast. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025077 on 21 February 2019. Downloaded from 
13Chua SYL, et al. BMJ Open 2019;9:e025077. doi:10.1136/bmjopen-2018-025077
Open access
nerve fiber layer atrophy in Parkinson’s disease. Ophthalmology 
2012;119:2161–7.
 90. Cunha LP, Almeida AL, Costa-Cunha LV, et al. The role of optical 
coherence tomography in Alzheimer’s disease. Int J Retina Vitreous 
2016;2:24.
 91. Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam 
Study: 2018 update on objectives, design and main results. Eur J 
Epidemiol 2017;32:807–50.
 92. Höhn R, Kottler U, Peto T, et al. The ophthalmic branch of the 
Gutenberg Health Study: study design, cohort profile and self-
reported diseases. PLoS One 2015;10:e0120476.
 93. Zhao D, Kim MH, Pastor-Barriuso R, et al. A longitudinal study of 
age-related changes in intraocular pressure: the Kangbuk Samsung 
Health Study. Invest Ophthalmol Vis Sci 2014;55:6244–50.
 94. Zhao D, Kim MH, Pastor-Barriuso R, et al. A longitudinal study 
of association between adiposity markers and intraocular 
pressure: The kangbuk samsung health study. PLoS One 
2016;11:e0146057.
 95. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 
million people: survey methods, baseline characteristics and long-
term follow-up. Int J Epidemiol 2011;40:1652–66.
 96. Patel AV, Jacobs EJ, Dudas DM, et al. The american cancer 
society’s Cancer Prevention study 3 (CPS-3): Recruitment, study 
design, and baseline characteristics. Cancer 2017;123:2014–24.
 97. Ouellette S, Tassé AM. P(3)G - 10 years of toolbuilding: From the 
population biobank to the clinic. Appl Transl Genom 2014;3:36–40.
 98. National Cancer institute Cohort Consortium. 2017. Available from: 
https:// epi. grants. cancer. gov/ Consortia/ cohort. html
 99. Psaty BM, O'Donnell CJ, Gudnason V, et al. CHARGE Consortium. 
Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium: Design of prospective meta-analyses of 
genome-wide association studies from 5 cohorts. Circ Cardiovasc 
Genet 2009;2:73–80.
 100. Bovenberg JA. Property rights in blood, genes & data naturally 
yours? Portland: Ringgold Inc, 2006.
 101. Willett WC, Blot WJ, Colditz GA, et al. Merging and emerging 
cohorts: not worth the wait. Nature 2007;445:257–8.
 102. Collins FS, Manolio TA. Merging and emerging cohorts: necessary 
but not sufficient. Nature 2007;445:259.
 103. UK Biobank. Access Procedures: application and review 
procedures for access to the UK Biobank Resource. http://www. 
ukbiobank. ac. uk/ resources/
by copyright.
 o
n
 Septem
ber 3, 2019 at Queen's University Belfast. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025077 on 21 February 2019. Downloaded from 
